Inflarx N.V. (IFRX) SEC Filings — 2025
14 SEC filings for Inflarx N.V. (IFRX) in 2025.
Filings
- InflaRx Updates Vilobelimab Phase 3 Data After Trial Termination — 6-K · Dec 30, 2025
- Inflarx N.V. 6-K Filing — 6-K · Nov 10, 2025
- InflaRx N.V. Faces Nasdaq Bid Price Non-Compliance — 6-K · Sep 12, 2025
- InflaRx N.V. Files 6-K, Incorporates Exhibits — 6-K · Aug 7, 2025
- InflaRx Faces Nasdaq Delisting Threat Over Low Share Price — 6-K · Jul 14, 2025
- InflaRx N.V. Changes Independent Auditor to KPMG — 6-K · Jun 27, 2025
- InflaRx Halts Phase 3 Trial for Vilobelimab Due to Futility — 6-K · May 28, 2025
- InflaRx N.V. Files 6-K for Registration Statement Incorporation — 6-K · May 7, 2025
- InflaRx N.V. Reports 2024 Annual Meeting Results — 6-K · Apr 24, 2025
- InflaRx N.V. Announces Annual Shareholder Meeting — 6-K · Apr 3, 2025
- InflaRx N.V. Files 2024 Annual Report — 20-F · Mar 20, 2025
- InflaRx N.V. Reports 2024 Results and Milestones — 6-K · Mar 20, 2025
- InflaRx N.V. Files 6-K for Share Offering — 6-K · Feb 18, 2025
- InflaRx N.V. Gets EU Approval for GOHIBIC® for ARDS — 6-K · Jan 15, 2025